Urology

Top Medical News
Novel device delivers improvements for BPH symptoms
Audrey Abella, Yesterday
The Optilume™ BPH Catheter System, a novel minimally invasive surgical therapy (MIST), provided rapid improvements for men with benign prostatic hyperplasia (BPH), the PINNACLE trial reports.
Early diagnosis is crucial
Stephen Padilla, 4 days ago
Severe dysmenorrhoea, pain related to urinary and gastrointestinal tracts, higher fertility desire and infertility rate are all associated with deep infiltrating endometriosis, according to a Singapore study. On the other hand, heavy menstrual bleeding is predictive of adenomyosis.
Use of monitoring tests remains low in prostate cancer
23 Mar 2023
Low use of recommended monitoring tests, including repeat prostate biopsy, persists among patients with localized prostate cancer undergoing observation, a recent study has found.
Response to therapy higher in clinical trial than real-world RCC patients
22 Mar 2023
Among patients with metastatic renal cell carcinoma (RCC) who have received first-line therapies, complete response rates are lower in the real-world population than in the clinical trial population, reports a recent study. Complete response predicts a favourable overall survival.
CBT, mindfulness help improve sexual outcomes in prostate cancer
21 Mar 2023
Mindfulness and cognitive behavioural therapy (CBT) appear beneficial for prostate cancer survivors and their partners who are dealing with sexual dysfunction, a study has shown.
Hydrochlorothiazide not better than placebo for preventing kidney stone recurrence
14 Mar 2023
Treatment with hydrochlorothiazide, regardless of dose, does not appear to significantly reduce the incidence of kidney stone recurrence as compared with placebo, according to a study.
Smoking, prolonged catheterization a major risk factor for UTI after radical hysterectomy
13 Mar 2023
For women with cervical cancer who are undergoing radical hysterectomy, preoperative tobacco use and prolonged catheterization appear to contribute to an increased risk of developing postoperative catheter-associated urinary tract infections (UTIs), as reported in a study.
Special Reports
Optimizing metastatic hormone-sensitive prostate cancer treatment in advanced prostate cancer
Assoc Prof. Darren Poon, Assoc Prof. Edmund Chiong, 14 Jan 2021
Metastatic hormone-sensitive prostate cancer (mHSPC) refers to the condition whereby patients have metastatic prostate cancer and no prior hormonal therapy or androgen deprivation therapy (ADT). Typically, patients with mHSPC have been treated with ADT alone, following which, the overwhelming majority develop castration resistance over time and head towards eventual mortality. In recent years, the publication of various landmark trials has prompted dramatic changes in the mHSPC treatment landscape, and had favourably impacted overall survival (OS) in these patients. At a recent webinar, A/Prof Darren Poon, Honorary Consultant in Clinical Oncology, Hong Kong Sanatorium & Hospital, and Honorary Clinical Associate Professor, Department of Clinical Oncology, The Chinese University of Hong Kong, reviewed treatment options in mHSPC, while A/Prof Edmund Chiong, Head and Senior Consultant, Department of Urology, National University Hospital, Singapore, presented a case which was discussed by an esteemed panel of experts. This webinar was jointly organized by the Singapore Society of Oncology and the Singapore Urological Association, and supported by Astellas. 
Conference Reports
Novel device delivers improvements for BPH symptoms
Audrey Abella, 31 Mar 2023
The Optilume™ BPH Catheter System, a novel minimally invasive surgical therapy (MIST), provided rapid improvements for men with benign prostatic hyperplasia (BPH), the PINNACLE trial reports.
mHSPC: Adding darolutamide to ADT and docetaxel ups OS in most disease volume and risk subgroups
Christina Lau, 10 Mar 2023

Triplet therapy with darolutamide, androgen-deprivation therapy (ADT) and docetaxel improves overall survival (OS) by approximately 30 percent vs ADT plus docetaxel in most disease volume and risk subgroups of patients with metastatic hormone-sensitive prostate cancer (mHSPC), a post hoc analysis of the phase III ARASENS trial has shown.

TRITON3: Rucaparib improves rPFS in BRCA-altered mCRPC
Elaine Soliven, 10 Mar 2023
Treatment with rucaparib significantly improved radiographic progression-free survival (rPFS) in patients with metastatic castration-resistant prostate cancer (mCRPC), particularly those with BRCA alterations, compared with the physician’s choice of therapy of docetaxel or a second-generation ARPI*, according to the TRITON3 trial presented at ASCO GU 2023.
CheckMate 274 follow up data boost nivolumab potential for high-risk bladder cancer
Audrey Abella, 08 Mar 2023
In the extended follow up of the phase III CheckMate 274 trial, nivolumab continued to show benefit for patients with muscle-invasive urothelial carcinoma (MIUC; bladder, ureter, or renal pelvis) who were at high risk for recurrence following bladder resection.
Darolutamide-containing triplet regimen ups survival in mHSPC regardless of disease volume, risk
Audrey Abella, 06 Mar 2023
In a post hoc analysis of the phase III ARASENS study, the triplet regimen comprising darolutamide, androgen deprivation therapy (ADT), and docetaxel continued to show overall survival (OS) benefit for metastatic hormone-sensitive prostate cancer (mHSPC) irrespective of disease volume and risk.
Rucaparib improves rPFS vs docetaxel or 2nd-generation ARPI in BRCA-mutated mCRPC
Christina Lau, 06 Mar 2023

Rucaparib significantly improves radiographic progression-free survival (rPFS) vs physician’s choice of docetaxel, abiraterone acetate or enzalutamide in patients with metastatic castration-resistant prostate cancer (mCRPC) harbouring BRCA alterations whose disease has progressed after treatment with a second-generation androgen-receptor pathway inhibitor (ARPI), results of the phase III TRITON3 trial have shown.

Neoadjuvant immunotherapy delivers in cisplatin-ineligible bladder cancer
Jairia Dela Cruz, 03 Mar 2023
The use of pembrolizumab in the neoadjuvant setting appears to be associated with a higher rate of downstaging and a survival advantage among patients with muscle-invasive bladder cancer (MIBC) who are ineligible for cisplatin-based neoadjuvant chemotherapy, according to a study presented at this year’s ASCO Genitourinary Cancers Symposium.